#37760 08-28-2004 05:00 PM | Joined: Jul 2004 Posts: 188 Likes: 1 Senior Member (100+ posts) | Senior Member (100+ posts) Joined: Jul 2004 Posts: 188 Likes: 1 | You might also search under IMC-C225, which was its pre- FDA approval name. This is the drug that contributed to all the Imclone trouble for Martha Stewart. It's a EGFR inhibitor similar in action to Iressa (aka ZD-1839) There's a pretty informative article on the ACS website date May 2004. They're saying that it has shown some pretty remarkable result in conjunction with Radiation in some pretty small studies (15 subjects), but this is the second EGFR inhibitor I've read about showing these kind of results, the other being Iressa.
Chuck
SCC Stage IV right tonsil T3N3M0. Dx 08/03. Clinical Trial:8 weeks Taxol, Carboplatin then Hydrea, 5FU, IMRT x's 48, SND, Iressa x 2yrs. Now 20 years out and thriving. Dealing with a Prostate cancer diagnosis now. Add a Bladder cancer diagnosis to all the fun. It's always something "Adversity doesn't build character, it reveals it." | | |
#37761 08-31-2004 04:35 PM | Joined: Jan 2003 Posts: 17 Member | Member Joined: Jan 2003 Posts: 17 | Does anyone know if there is a test to determine if an individual is expressing EGF (?epidermal or epithelial growth factor) or has a tumor that has the receptors for it? It seems to me those are the tumors Erbitux would specifically hit. nannygranny6 | | |
#37762 08-31-2004 08:06 PM | Joined: Nov 2002 Posts: 3,552 Patient Advocate (old timer, 2000 posts) | Patient Advocate (old timer, 2000 posts) Joined: Nov 2002 Posts: 3,552 | The data that they have acquired with Iressa, which also targets the epidermal growth factor receptor (EGFR), is that it only works 10% of the time. 90% have no benefit. These studies were done with lung cancer patients (which it was designed for) with adenocarcinoma and only as a last resort after conventional forms of treatment have failed. It has shown very dramatic results in some patients. They are trying it with H&N patients. I have no idea of the success rates.
Gary Allsebrook *********************************** Dx 11/22/02, SCC, 6 x 3 cm Polypoid tumor, rt tonsil, Stage III/IVA, T3N0M0 G1/2 Tx 1/28/03 - 3/19/03, Cisplatin ct x2, IMRT, bilateral, with boost, x35(69.96Gy) ________________________________________________________ "You are a mist that appears for a little while and then vanishes" (James 4:14 NIV)
| | |
#37763 09-01-2004 02:40 PM | Joined: May 2002 Posts: 2,152 Patient Advocate (old timer, 2000 posts) | Patient Advocate (old timer, 2000 posts) Joined: May 2002 Posts: 2,152 | I called IMCLONE on this drug when I had my second dx in July 2001. I think they or the oncologist told me that the success rate for H&N patients was about 25% when combined with radiation. They had been running clinical trials at the time but they had just closed at Penn and I couldn't have more radiation so abandoned the idea. I opted for surgery. There had also been an article earlier in the year in the NY Times on the success of UC225, as it was called then, on its success in both cholorectal and H&N cancers. I don't know what the recent trials have revealed.
Eileen
---------------------- Aug 1997 unknown primary, Stage III mets to 1 lymph node in neck; rt ND, 36 XRT rad Aug 2001 tiny tumor on larynx, Stage I total laryngectomy; left ND June 5, 2010 dx early stage breast cancer June 9, 2011 SCC 1.5 cm hypo pharynx, 70% P-16 positive, no mets, Stage I
| | |
Forums23 Topics18,249 Posts197,138 Members13,323 | Most Online1,788 Jan 23rd, 2025 | | | |